Despite dramatic improvements in treatment outcomes over the last couple of years, chronic lymphocytic leukemia (CLL) has remained an incurable disease that requires intermittent therapy during episodes of disease progression.¹ In patients with relapsed/refractory (rr) CLL, treatment options often i

Although chronic lymphocytic leukemia (CLL) patients now have a broader selection of treatment options available, therapeutic efficacies of most treatments still largely depend on the patients’ fitness, cytogenetics and previous treatment responses. Some clinically relevant mutations have now been identified to predict